Navigation Links
Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
Date:4/21/2008

g out of the accounting issues described in the Company's filings with the Securities and Exchange Commission (SEC), the difficulty of predicting FDA filings and approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, uncertainty of patent litigation filed against the Company, availability of raw materials, the regulatory environment, fluctuations in operating results and other risks and uncertainties detailed from time to time in the Company's filings with the SEC, such as the Company's reports on Form 10-K, Form 10-Q and Form 8-K, and amendments thereto. Any forward-looking statements included in this press release are made as of the date hereof only, based on information available to the Company as of the date hereof, and, subject to any applicable law to the contrary, the Company assumes no obligation to update any forward-looking statements.

*MYCELEX(R) is a registered trademark of Bayer Healthcare LLC


'/>"/>
SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
2. Shareholder Class Action Filed Against Vertex Pharmaceuticals Incorporated by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
5. Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
6. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
7. Rib-X Pharmaceuticals Renews Collaborative Agreement with the Medical Research Council
8. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
9. Antipodean Pharmaceuticals Announces Completion of Phase 2 Study of Lead Compound MitoQ(R)
10. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
11. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Colo. , Aug. 28, 2014   Venaxis, ... company focused on obtaining FDA clearance for and commercializing ... blood test for aiding in identifying children, adolescent, and ... at low risk for appendicitis, today announced it will ... Renshaw 16 th Annual Global Investment Conference being ...
(Date:8/28/2014)... YORK , Aug. 28, 2014 ... new market research report is available ... Multiforme Therapeutics in Asia-Pacific Markets to ... High Unmet Need in Newly Diagnosed ... http://www.reportlinker.com/p02343492/Glioblastoma-Multiforme-Therapeutics-in-Asia-Pacific-Markets-to-2020---Novel-Therapeutic-Approaches-Target-High-Unmet-Need-in-Newly-Diagnosed-and-Recurrent-GBM.html ...
(Date:8/28/2014)... MAHWAH, N.J. , Aug. 28, 2014  Stryker Orthopaedics, ... Champions Tour, is bringing its message of joint health to ... Playoffs this week at the Deutsche Bank Championship. The company,s ... in the "Fairway Fan Zone on 9" at the TPC ... Thursday, August 28 th .    At the ...
Breaking Medicine Technology:Venaxis to Present at September Investor Conferences 2Venaxis to Present at September Investor Conferences 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 2Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 6Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 7Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 8Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 9Stryker, Official Joint Replacement Products Of The PGA TOUR, Heads To Boston For The Deutsche Bank Championship 2Stryker, Official Joint Replacement Products Of The PGA TOUR, Heads To Boston For The Deutsche Bank Championship 3Stryker, Official Joint Replacement Products Of The PGA TOUR, Heads To Boston For The Deutsche Bank Championship 4Stryker, Official Joint Replacement Products Of The PGA TOUR, Heads To Boston For The Deutsche Bank Championship 5
... 2007 - OSI,Pharmaceuticals, Inc. (Nasdaq: OSIP) announced ... of Clinical Oncology show that,adding Tarceva(R) (erlotinib) ... as first-line,therapy to patients with advanced pancreatic ... National Cancer Institute of Canada (NCIC),formed the ...
... STRASBOURG, France and VANCOUVER, April 26, 2007,/PRNewswire-FirstCall/ ... pharmaceutical and medical device company, announced that,the ... examining the,Vascular Wrap(TM) Paclitaxel-Eluting Mesh ("Vascular Wrap(TM)"),will ... in Europe. The,two-year study examined the safety ...
Cached Medicine Technology:OSI Pharmaceuticals Announces Pivotal Phase III Tarceva Study,Published in the Journal of Clinical Oncology Showed Survival,Improvement in Patients with Pancreatic Cancer 2OSI Pharmaceuticals Announces Pivotal Phase III Tarceva Study,Published in the Journal of Clinical Oncology Showed Survival,Improvement in Patients with Pancreatic Cancer 3OSI Pharmaceuticals Announces Pivotal Phase III Tarceva Study,Published in the Journal of Clinical Oncology Showed Survival,Improvement in Patients with Pancreatic Cancer 4Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 2Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 3Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 4Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 5Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 6Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 7
(Date:8/28/2014)... researchers place glue directly on the nerve stumps, but ... and allows glue to easily invade the nerve ends. ... to insert the nerve ends into the conduit because ... Xiangdang Liang and co-workers from the General Hospital of ... technique and defined the best parameters for its use ...
(Date:8/28/2014)... 2014 One in every 200 Ontarians has been ... of people living with the disease increasing by 64 ... study by researchers at the Institute for Clinical Evaluative ... and the Ottawa Hospital Research Institute. That puts Ontario ... world. , The study, published this week in ...
(Date:8/28/2014)... BCC Research ( http://www.bccresearch.com ) reveals in ... GLOBAL MARKETS , the global market for surgical navigation ... by the need for replacement of existing installations and ... the market is expected to grow to $631.9 million ... from 2013 through 2018. , While revenue generation will ...
(Date:8/28/2014)... Port Washington, New York (PRWEB) August 28, 2014 ... law firm that has spent many years fighting to ... comments that the decision to provide coverage to WTC ... report released by the U.S. Government Accountability Office (GAO). ... Watch on August 25th, the report is entitled ...
(Date:8/28/2014)... Clarity PSO , an operating division ... federal Patient Safety Organization (PSO) for another three-year period ... and Quality (AHRQ). Clarity PSO will continue to provide ... the true intentions of the Patient Safety and Quality ... and eager to continue our journey as a PSO ...
Breaking Medicine News(10 mins):Health News:Ontario has one of the highest rates of IBD in the world 2Health News:Global Market for Surgical Navigation Systems Expected to Reach $631.9 Million in 2018; ENT Systems Segment Leading With 10.4% CAGR 2Health News:Global Market for Surgical Navigation Systems Expected to Reach $631.9 Million in 2018; ENT Systems Segment Leading With 10.4% CAGR 3Health News:GAO Report Reaffirms Decision to Add Cancers to List of Illnesses Covered under the Zadroga Act, Parker Waichman LLP Comments 2Health News:GAO Report Reaffirms Decision to Add Cancers to List of Illnesses Covered under the Zadroga Act, Parker Waichman LLP Comments 3Health News:Clarity PSO Re-lists as a Patient Safety Organization and Continues to Advance Patient Safety 2Health News:Clarity PSO Re-lists as a Patient Safety Organization and Continues to Advance Patient Safety 3
... By Kathleen Doheny HealthDay Reporter , FRIDAY, ... Friday could shake up the debate on whether or not ... One study, presented at the annual meeting of ... that screening women aged 40 to 49 with mammograms detected ...
... Video games controlled by the player,s breath can encourage youths ... their airways clearer, according to a study to be presented ... meeting in Denver. Cystic fibrosis, one of the ... causes mucus to build up in the lungs and digestive ...
... DENVER When adolescent females visit a pediatric emergency ... infection (STI), white youths are less likely to be ... presented Saturday, April 30, at the Pediatric Academic Societies ... by Carolyn K. Holland, MD, MEd, previously found that ...
... anxiety. Patient discomfort may cause poor image quality ... medications are currently used to reduce this anticipated anxiety ... treatment with fewer adverse effects, according to an exhibit ... annual meeting. The project was conceived by a ...
... surgery has become a mainstream tool for removing an ever-increasing ... head and neck surgeons from Mayo Clinic has found robotic ... the tongue at the top of the voice box. ... or radiation, and most could resume normal eating and speaking. ...
... HealthDay Reporter , FRIDAY, April 29 (HealthDay News) -- ... opted for a double mastectomy as a precautionary measure ... Researchers at the Mayo Clinic in Rochester, Minn., ... in the hope of avoiding another cancer. Twenty years ...
Cached Medicine News:Health News:Mammograms Can Save Lives of Women in Their 40s: Studies 2Health News:Mammograms Can Save Lives of Women in Their 40s: Studies 3Health News:Mammograms Can Save Lives of Women in Their 40s: Studies 4Health News:Video games may help clear airway of cystic fibrosis patients 2Health News:Race a factor in whether young women are tested for sexually transmitted infections 2Health News:Animal-assisted therapy decreases patient anxiety in pre-MRI setting, study suggests 2Health News:Mayo Clinic finds robotic surgery effective for removing hard-to-reach throat cancer 2Health News:Most Cancer Survivors Would Sacrifice Healthy Breast Again: Study 2Health News:Most Cancer Survivors Would Sacrifice Healthy Breast Again: Study 3
Designed for simple operation, the Model 515B pulse oximeter is ideal for use in any clinical setting; from emergency hospital transport to continuous monitoring in Anesthesia, Intensive Care and Gen...
... The Models 512 and 513 handheld ... This advanced technology is able to ... resolutions and speeds of 100 times ... in improved pulse oximeter performance during ...
... Whether it's for an emergency situation, bedside ... Handheld Capnograph / Pulse Oximeter delivers accurate ... This portable, handheld monitor now contains Nellcors ... compatible with OxiMax sensors. The NPB-75 monitor ...
The new Nellcor N-45 Handheld Pulse Oximeter is compatible with our complete line of OxiMax Pulse Oximetry Sensors, so clinicians have the convenience of Nellcors most advanced sensor technology in a...
Medicine Products: